We recently compiled a list of the 10 Worst Performing Healthcare Stocks in 2024. In this article, we are going to take a ...

Two significant legal decisions have come or are coming into force over the next couple of weeks in the UK and Europe.

November is National Alzheimer’s Awareness Month.The Alliance for Aging Research is using this month to raise awareness about ...

Buoyed by a strong performance in its core private hospital business and a surge in sales of its tracer drug NeuraCeq, Life ...

Eisai and the National Center of Neurology and Psychiatry in Tokyo will study the link between APOE genotype and safety and efficacy of Leqembi.

The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...

Anavex Life Sciences (AVXL) stock rises 10% in premarket as company submits EU marketing application for Alzheimer's drug ...

Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s ...

Alzheimer's wonder drugs aren't yet delivering on their promise. American researchers have come up with a brand new idea, a ...

Rosa-Grilo incorporated Wave-CAIPI into the diagnostic scanning protocol used at UCL’s memory clinic. It comprises four sequences: T1-weighted 3D, T2-weighted 2D, T2-weighted 3D, and 3D FLAIR imaging.

Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...